MetLife, Inc. (NYSE: MET), one of the world's largest life insurance and employee benefits providers, has spent 2026 climbing steadily out of the mid-$60s, where it began the 52-week period. With shares now trading in the mid-$90s and having touched an all-time high just under $98, the round number of $100 has become the natural question for traders and long-term investors alike. A move to triple digits would mark both a psychological milestone and a confirmation that the stock's long-term uptrend remains intact.
Founded in 1868 and headquartered in New York, MetLife operates through segments spanning Group Benefits, Retirement and Income Solutions (RIS), Asia, and MetLife Holdings. The company has been executing a "New Frontier" strategy aimed at double-digit earnings-per-share (EPS) growth and a higher long-term return on equity, while leaning into capital-light businesses such as pension risk transfers and retirement income agreements. Its roughly $61 billion market capitalization and forward dividend yield near 2.5% place it among the largest and most widely followed names in the financial services sector.
Several verified factors support the case for MET reaching $100. Analysts surveyed by S&P Global project EPS growth of roughly 11% this year and again next year, reflecting strength in group benefits and retirement solutions. In August 2026, the company announced a $3 billion share repurchase program, a meaningful capital-return signal that tends to support both earnings per share and investor sentiment. Rising interest rates historically benefit insurers by boosting investment income, though rate sensitivity cuts both ways depending on the macro backdrop.
Acquisition-driven expansion has also contributed to the re-rating. MetLife's purchase of asset manager PineBridge Investments added scale to its investment-management capabilities, reinforcing the capital-light strategic shift that investors have rewarded with a higher valuation multiple.
The most immediate obstacle is technical rather than fundamental: MET must convincingly clear its prior record high near $98 before $100 comes into view. A failed breakout at that zone could trap momentum and send shares back toward the $91–$93 support level. Broader risks include a meaningful decline in long-term interest rates, which would pressure investment income, and potential credit deterioration in commercial real estate holdings. Insurers' investment portfolios can also face volatility during equity-market downturns, and regulatory changes remain an ever-present consideration for the industry.
Wall Street's view is constructive. The consensus rating for MET is "Buy," with an average 12-month price target near $105, according to analyst data compiled by S&P Global. Individual targets have been climbing through August 2026, with Morgan Stanley at $111, Wells Fargo at $109, Mizuho at $112, and J.P. Morgan and KBW both at $108. Even the lowest published targets sit near $84, above the stock's starting point for the year. This clustering of targets above $100 suggests professional analysts broadly expect the stock to trade through that milestone, though such forecasts represent opinions rather than guarantees.
From a technical analysis perspective, the picture is defined by a clear long-term uptrend. The all-time high near $98 is the primary resistance level; a decisive close above it would likely open the path to $100 and beyond. On the downside, the $91–$93 area has provided recent support, with the $90 round number serving as a secondary floor. Because MET is trading near record territory, there is little overhead supply from prior holders, which generally improves the odds of a sustained breakout once the high is cleared.
For investors monitoring whether MET can reach its target, Tickeron's AI Daily Buy/Sell Signals offer an additional layer of insight. The product uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to surface new opportunities, track existing positions, and identify changing market trends more efficiently than manual review allows. Exploring these AI-generated signals may help investors stay ahead of evolving momentum in names like MetLife.
Reaching $100 is a realistic, medium-term objective for MetLife rather than a stretch goal. The strongest supporting factors are a consensus Buy rating with an average target above $100, double-digit forecast EPS growth, a sizable buyback, and a long-term uptrend near record highs. The primary risks are a failure to clear the prior high near $98, a sharp drop in interest rates, or credit stress in the investment portfolio. Investors should monitor whether MET can close above its all-time high on sustained volume, as well as upcoming earnings and any changes to capital-return plans, to gauge whether the push toward triple digits remains on track.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, MET has been closely correlated with PRU. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if MET jumps, then PRU could also see price increases.